Novartis shoots for early OK of a ‘breakthrough’ blood cancer drug after reversing organ damage in trial
Up to now, Novartis’ midostaurin has been primarily noted for its potential in treating a mutation-specific type of acute myeloid leukemia, thrust into the spotlight after the FDA handed out its breakthrough designation for the drug earlier this year. But a new study shows that the drug also demonstrated a statistically significant ability to halt and reverse organ damage caused by rare cases of advanced systemic mastocytosis. And the pharma giant now plans to prep an application for regulators on both sides of the Atlantic in search of early marketing approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.